Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosis

Anticancer Research

Volumn 16, Issue 2, 1996, Pages 1027-1032

  Albanell, Joan ^a,c   Bellmunt, Joaquim ^a   Molina, Rafael ^b   García, Magdalena ^a   Caragol, Isabel ^a   Bermejo, Begoña ^a   Ribas, Antoni ^a   Carulla, Joan ^a   Gallego, O S ^a   Español, Teresa ^a   Solé Calvo, Luis A ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adjuvant therapy; Breast cancer; HER2 neu; p53; Prognosis

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CELL CYCLE S PHASE; CLINICAL TRIAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; ONCOGENE NEU; PLOIDY; PRIORITY JOURNAL; PROGNOSIS;

AGE FACTORS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTOR, ERBB-2; RISK; TUMOR SUPPRESSOR PROTEIN P53;

EID: 8944232866     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339: 1-15, 71-85, 1992
2. Henderson IC. Adjuvant systemic therapy for early breast cancer. Cancer 74: 401-409, 1994
3. Mansour EG, Ravdin PM, Dressler L. Prognostic factors in early breast cancer. Cancer 74: 381-400, 1994
4. Rosen PP, Groshen S, Kinne DW, et al. Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol 11: 2090-2100, 1993
5. Bishop JM. The molecular genetics of cancers. Science 235: 305-311, 1987
6. Chang F, Syrjänen S, Syrjänen K. Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 13: 1009-1022, 1995
7. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
8. DiFiore PP, Pierce JH, Kraus MH, et al. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237: 178-182, 1987.
9. Baselga J, Tripathy D, Mendelsohn J, et al: Phase II study of recombinant anti-HER monoclonal antibody (rhuMAb HER2) in stage IV breast cancer (BC): HER2-shedding dependent pharmacokinetics and antitumor activity. Proc Am Soc Clin Oncol 14: 113A, 1995.
10. Knoop AS, Laenkholm A-V, Mirza MR, et al: Prognostic and predictive factors in early breast cancer. In: ESMO Educational Book II, Lisbon p 9-18, 1994.
11. Descotes F, Pavy JJ, Adessi GL. Human breast cancer: correlation between Her-2/neu amplification and prognostic factors in an unselected population. Anticancer Res 13: 119-124, 1993.
12. Scorilas A, Yotis J, Gouriotis D, et al: Cathepsin-D and c-erb-B2 have an additive prognostic value for breast cancer patients. Anticancer Res 13: 1895-1900, 1993.
13. Scorilas A, Yotis J, Stravolemos K, et al: c-erbB-2 overexpression may be used as an independent prognostic factor for breast cancer patients. Anticancer Res 15: 1543-1548, 1995.
14. Isola J, Visakorpi T, Holli K, et al: Association of overexpression if tumor suppressor protein with rapid proliferation and poor prognosis in node-negative breast cancer patients. J Nat Cancer Inst 84: 1109-114, 1992.
15. Rosen PP, Lesser ML, Arroyo CD, et al: p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. J Clin Oncol 13: 821-830, 1995.
16. Marks JR, Humphrey PA, Wu K, et al: Overexpression of p53 and HER2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg 219: 332-341, 1994.
17. Iwaya K, Tsuda H, Hiraide H, et al: Nuclear p53 immunoreaction associated with poor prognosis breast cancer. Jpn J Cancer Res 82: 835-840, 1991.
18. Fisher ER, Gregorio RM, Fisher B. The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer 36: 1-85, 1975.
19. Bloom HG, Richardson WW. Histological grading and prognosis. Br J Cancer 11: 359-377, 1957.
20. O'Reilly SM, Camplejohn RS, Barnes DM, et al: DNA index. S-phase fraction, histological grade and prognosis in breast cancer. Br J Cancer 61: 671-674, 1990.
21. O'Reilly SM, Camplejohn RS, Barnes DM, et al: Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry. J Clin Oncol 8: 2040-2046, 1990.
22. Molina R, Ciocca DR, Tandon AK, et al: Expression of HER-2/neu oncoprotein in human breast cancer: a comparison of immunohistochemical and Western blot techniques. Anticancer Res 12: 1965-1972, 1992.
23. Bαrtek J, Bαrtkova J, Vojtesek B, et al: Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6: 1699-1703, 1991.
24. Langton BC, Tran K, Jackson J, et al: The development and characterization of antibodies to different regions of the c-erbB-2 protein in breast tumor tissue and cell lines. Proc Am Assoc Cancer Res 30: 352A, 1989.
25. Martin M, Villar A, Soli LA, et al: A randomized trial comparing CMF with FAC in breast cancer adjuvant treatment. Toxicity analysis. Ann Oncol 5(S8): 21A, 1994.
26. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. Am Stat Assoc J 53: 547-81, 1958.
27. Thor AD, Moore DH, Edgerton SM, et al: Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Nat Cancer Inst 84: 844-855, 1992.
28. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogene. Science 235: 177-182, 1987.
29. Gusterson BA, Gelber RD, Goldirsch A, et al: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10: 1049-1056, 1992.
30. Seshadri R, Firgaira FA, Horsfall DJ, et al: Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 11: 1936-1942, 1993.
31. Rosen PP, Lesser ML, Arroyo CD, et al: Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. Cancer 75: 1320-1326, 1995.
32. Allred DC, Clark GM, Tandon AK, et al: HER-2/new in node-negative breast cancer. Prognostic significance of overexpression influenced by presence of in situ carcinoma. J Clin Oncol 10: 599-605, 1992.
33. Muss HB, Thor AD, Berry DA, et al: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330: 1260-1266, 1994.
34. Allred DC, Clark GM, Elledge R, et al: Association of p53 expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Nat Cancer Inst 85: 200-206, 1993.
35. Caleffi M, Teague MW, Jensen RA, et al: p53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment. Cancer 73: 2147-2156, 1994.
36. Gasparini G, Weidner N, Bevilacqua P, et al: Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 12: 454-466, 1994.
37. Cho Y, Gorina S, Jeffrey PD, et al: Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265: 346-355, 1994.